0310 GMT - Colgate-Palmolive (India) stands to benefit from some tailwinds, Nomura analysts say in a research report. The Indian company's core product portfolio is recovering to normal levels from below-normal levels in FY 2026 and it's doubling down on product premiumization, the analysts note. The oral care products manufacturer's revenue growth momentum is likely to improve and return to near double digits in FY 2027 from flat in FY 2026. Nomura lifts its FY 2027 and FY 2028 EPS estimates for Colgate-Palmolive (India) by around 7% and 10%, respectively. It raises the stock's rating to buy from reduce and the target price to 2,500.00 rupees from 2,050.00 rupees. Shares last closed at 2,157.50 rupees. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
May 24, 2026 23:10 ET (03:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments